https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37096 Wed 17 Nov 2021 16:30:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48377 Wed 15 Mar 2023 13:54:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47146 Wed 14 Dec 2022 15:27:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30351 1 or CGRP₂ receptor in which it demonstrates similar high-affinity binding for salmon calcitonin, CGRP, and amylin, a possession which is not shared by any extra CGRP receptors. Binding of CGRP to its receptor increases activated cAMP-dependent pkA and PI3 kinase, resulting in N-terminal fragments that are shown to exert complex inhibitory as well facilitator actions on nAChRs. Fragments such as CGRP1-4, CGRP1-5, and CGRP1-6 rapidly as well as reversibly improve agonist sensitivity of nAChRs without straight stimulating those receptors and produce the Ca²⁺-induced intracellular Ca²⁺ mobilization. Renin–angiotensin–aldosterone system (RAAS)-activated angiotensin-type (AT4) receptor is also beneficial in AD. It has been suggested that exogenous administration of CGRP inhibits infiltration of macrophages and expression of various inflammatory mediators such as NFkB, IL-1b, TNF-α, iNOS, matrix metalloproteinase (MMP)-9, and cell adhesion molecules like intercellular adhesion molecule (ICAM)-1 which attenuates consequence of inflammation in AD. Donepezil, a ChEI, inhibits acetylcholinesterase and produces angiogenesis and neurogenesis, in the dentate gyrus of the hippocampus of WT mice after donepezil administration. However, none of the results discovered in CGRP-knockout mice and WT mice exposed to practical denervation. Therefore, selective agonists of CGRP receptors may become the potential candidates for treatment of AD]]> Wed 10 Nov 2021 15:13:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54046 Tue 30 Jan 2024 13:50:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41998 Tue 16 Aug 2022 16:37:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36990 Thu 28 Oct 2021 12:36:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33592 Auricularia polytricha is a popular mushroom found all over the world. In this study we considered the effect of an aqueous extract of A. polytricha (AEAP) on restoring sexual performance parameters to normal, evaluated by considering observations of sexual behavior. At 0, 6, 12, 18, and 24 days, the following parameters of sexual performance were identified before and throughout the observations: mount latency, intromission latency, ejaculation latency, mounting frequency, intromission frequency, ejaculation frequency, and postejaculatory interval. Treatment of rats under stress with AEAP showed promising effects on overcoming stress-induced sexual dysfunction, on sexual performance, and on accessory sexual organs and body weight. Mounting latency, intromission latency, ejaculation latency, and postejaculatory interval parameters were significantly decreased by AEAP, whereas mounting frequency, intromission frequency, and ejaculation frequency were significantly increased by AEAP. These properties were identified in sexually dynamic and indolent male rats. We conclude that AEAP has a potent aphrodisiac activity.]]> Thu 22 Nov 2018 13:41:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31020 Sat 24 Mar 2018 07:34:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46616 Mon 28 Nov 2022 10:47:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44588 Mon 17 Oct 2022 13:57:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41301 Mon 01 Aug 2022 12:16:33 AEST ]]>